Indication: Glioblastoma
EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Sub-indication: CNS Cancer
Study Type: Device Study
Principal Investigator: Renato LaRocca, M.D.Norton Brain Tumor Center
Sponsor: Sponsor: NovoCure
Learn more at ClinicalTrials.gov
Email for more information: CNS-NCIResearch@nortonhealthcare.org